Drug, sold under the brand name Veklury, approved for hospital use in adults and children aged 12 and above

WHO’s Solidarity trial, spanning 30 countries, found the drug had little effect on mortality, reducing the length of hospital stays or need for a ventilator

Remdesivir, the antiviral drug developed by American firm Gilead Sciences, has become the first in the United States to be approved for use in the treatment of

patients, days after the World Health Organization (WHO) said it offered limited benefits.

Following an emergency use authorisation (EUA) issued on May 1, the drug, sold under the brand name Veklury, was approved for hospital use in adults and children aged 12 and above, the US Food and Drug Administration (FDA) said on Thursday.

The EUA was altered to allow for continued access for children weighing at least 3.5kg but not more than 40kg, or hospitalised paediatric patients under 12 and weighing at least 3.5kg. Clinical trials assessing the safety and efficacy of Veklury in the paediatric patient population were ongoing, the statement said.

An EUA refers to the practice by which unapproved medical products or unapproved uses of approved medical products are permitted in emergency situations.

Veklury was granted conditional approval by the

and Australia in July for treating adult and adolescent Covid-19 patients with severe symptoms in hospital. US President Donald Trump was given the drug earlier this month.

The FDA said the approval was based on analysis of data from three clinical trials using people with mild to severe symptoms.

One of the trials, conducted by the National Institute of Allergy and Infectious Diseases, showed recovery from Covid-19 was 10 days for the Veklury group compared to 15 days for a placebo group.

The results were published in the

this month.

The approval came just days after the WHO’s Solidarity trial, involving more than 11,000 people in 405 hospitals in 30 countries, found the drug had little effect on mortality, reducing the length of hospital stays or whether patients needed a ventilator.

The results of the study were made public before being peer-reviewed.

David Hui, an expert in respiratory medicine at Chinese University of Hong Kong, questioned the results of the WHO trial.

“The Solidarity trial was limited by several major factors: no data monitoring, no placebo control, no double-blinding, no diagnostic confirmation of infection. It has very poor study design,” he said.

“The trial with placebo control published in

showed that remdesivir can shorten the duration of illness by five days and this is an important endpoint.”

Gilead Sciences said last week that the Solidarity trial was a “multi-centre, open-label global trial designed to provide early access to remdesivir to patients around the world and the trial design prioritised broad access, resulting in significant heterogeneity in trial adoption, implementation, controls and patient populations”.

Paul Sax, a professor of medicine at Harvard Medical School wrote in

that the greatest benefit of remdesivir would be in patients with shorter duration of symptoms, whereas the Solidary trial began enrolment in March and for much of the enrolment period, patients with Covid-19 did everything they could to avoid going to hospital.

“For many, I suspect the short window of time for this antiviral to benefit had closed by the time they were admitted,” he said.

Whether remdesivir actually worked was “a cautious maybe”, Sax said, adding he would still recommend it for most people being treated in hospital.

“But if we can learn anything from the mental gyrations required to square these conflicting study results, it’s that we definitely need more effective options.”

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Why women dying in jail are among the less visible victims of Covid-19

Melissa Ann Horn’s name appeared over and over in court records and jail blotters in the rural Virginia county where she was born, and where she was arrested for crimes related to her struggles with meth and money. When she…

Former congressman, Olympian Jim Ryun on receiving Presidential Medal of Freedom: ‘I’m very grateful’

Trump awards the Presidential Medal of Freedom to a three-time Olympian and former GOP congressman from Kansas; Jim Ryun and his son Ned join ‘Fox & Friends Weekend.’ Receiving the Presidential Medal of Freedom was “very special” and an “opportunity…

President calls for greater debt relief for poorer countries in wake of Covid-19

The head of the World Bank has called for a more ambitious debt relief plan for poor countries after warning that the Covid-19 recession is turning into a depression in the most challenged parts of the globe. In an interview…

Kim Kardashian sells $200m stake in cosmetics brand

Reality TV star and socialite Kim Kardashian West has sold a $200m ($160m) stake in her cosmetics business to the French beauty giant Coty. The star said the deal would help her reach a bigger global audience but she would…